RxDoctor Payments Data

Sara Zarei, MD

Neurology · Orange, CANPI 1417416637

Payments from drug & device makers

$5,896in general payments, 2019–2025

Across 238 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$984
  • AbbVie$630
  • Biogen$501
  • AstraZeneca$397
  • Bristol Myers Squibb$276
  • Argenx US, Inc.$243
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,76398%
  • Education$1332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,896 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$14,585
Medicare patients
28
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcrevusOcrelizumab14$505,745
Kesimpta PenOfatumumab36$411,743
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$125,143
VumerityDiroximel Fumarate13$105,499
CopaxoneGlatiramer Acetate12$70,177
QuliptaAtogepant24$24,430
RexultiBrexpiprazole15$19,928
Nurtec OdtRimegepant Sulfate18$18,220
UbrelvyUbrogepant13$12,230
Dalfampridine ErDalfampridine24$10,798
ZtlidoLidocaine19$8,078
Gabapentin106$1,207
Baclofen57$1,120
Celecoxib148$1,061
Pyridostigmine Bromide11$691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Ocrevus$31$505,74514 claims
BiogenVumerity$501$105,49913 claims
AbbVieQulipta, Ubrelvy$630$36,66037 claims
Otsuka America Pharmaceutical, Inc.Rexulti$65$19,92815 claims
PfizerNurtec Odt$231$18,22018 claims
Scilex Pharmaceuticals Inc.Ztlido$43$8,07819 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$131$69111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →